A Comparison of the Effects of Selective and Non Selective Mineralocorticoid Antagonism on Glucose Homeostasis and Lipid Profile of Heart Failure Patients With Glucose Intolerance or Type 2 Diabetes.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Apr 2017
At a glance
- Drugs Eplerenone; Spironolactone
- Indications Diabetes mellitus; Glucose metabolism disorders; Heart failure
- Focus Pharmacodynamics
- Acronyms SNOW
- 10 Jun 2017 Biomarkers information updated
- 27 Mar 2017 Planned End Date changed from 1 Jul 2016 to 1 Mar 2018.
- 16 Dec 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2016 as reported by ClinicalTrials.gov record.